143 related articles for article (PubMed ID: 36998440)
1. Response to selpercatinib in a patient with
Arora A; Zaemes J; Ozdemirli M; Kim C
Front Oncol; 2023; 13():1134151. PubMed ID: 36998440
[TBL] [Abstract][Full Text] [Related]
2. Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer.
Huang Y; Dai S; Yin W; Luo F; Li Y
Onco Targets Ther; 2023; 16():1015-1020. PubMed ID: 38050583
[TBL] [Abstract][Full Text] [Related]
3. A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring
Qin H; Wan Y; Dong Y; Sun Q
Cancer Manag Res; 2023; 15():765-769. PubMed ID: 37525669
[TBL] [Abstract][Full Text] [Related]
4. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage
Goldman JW; Sholl LM; Dacic S; Fishbein MC; Murciano-Goroff YR; Rajaram R; Szymczak S; Szpurka AM; Chao BH; Drilon A
Front Oncol; 2023; 13():1178313. PubMed ID: 37274265
[TBL] [Abstract][Full Text] [Related]
6. RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report.
Pishdad R; Illei PB; Gocke CD; Ball DW
Front Oncol; 2024; 14():1360492. PubMed ID: 38469239
[TBL] [Abstract][Full Text] [Related]
7. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
8. Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report.
Meng Z; Zhang C; Zuo R; Zhu F; Wang Y; Mi R; Zhang M; Chen P
Anticancer Drugs; 2022 Aug; 33(7):682-685. PubMed ID: 35324532
[TBL] [Abstract][Full Text] [Related]
9. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
[TBL] [Abstract][Full Text] [Related]
10. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
[TBL] [Abstract][Full Text] [Related]
11. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
Nie T; Syed YY
Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
[TBL] [Abstract][Full Text] [Related]
12. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
13. Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer.
Yokota T
Case Rep Oncol; 2022; 15(3):833-840. PubMed ID: 36825106
[TBL] [Abstract][Full Text] [Related]
14. Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
Wang Y; Chen Y; Yang Z; Qian F; Hu M; Lu J; Zhang Y; Zhang W; Wang K; Han B
Ann Surg Oncol; 2022 Sep; 29(9):5666-5678. PubMed ID: 35543906
[TBL] [Abstract][Full Text] [Related]
15. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
[TBL] [Abstract][Full Text] [Related]
16. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report.
Wu Y; Yan Z; Pan J; Chang X; Huang B; Luo D; Meng R; Shi H; Fan J; Nie X
World J Surg Oncol; 2022 Dec; 20(1):386. PubMed ID: 36471407
[TBL] [Abstract][Full Text] [Related]
17. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
Nguyen VQ; Geirnaert M
J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
[TBL] [Abstract][Full Text] [Related]
19. Selpercatinib and capmatinib combination promotes sustained complete response in novel
Leite CA; Carvalho RP; da Costa FM; Medeiros AK; Schutz FA; William WN
Front Oncol; 2023; 13():1264231. PubMed ID: 37876974
[No Abstract] [Full Text] [Related]
20. Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges.
Andrini E; Marchese PV; De Biase D; Mosconi C; Siepe G; Panzuto F; Ardizzoni A; Campana D; Lamberti G
J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
